Bispecifics keep the business development fires burning
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
After Takeda endorsement Curadev’s Sting attracts Bayer
The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
Immatics and Molmed become the subjects of very different deals
Two acquisitions of cell therapy companies could take them in almost opposite directions.
Thermo Fisher buys Qiagen after all
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
CD47 is worth $4.9bn to Gilead
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.
Another preclinical thumbs-up for Sangamo’s zinc fingers
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
Collaborative diabetes tech on the Horizon
For diabetes devices interoperability is key, and partnerships between Insulet, Dexcom and Abbott show that rival groups see the benefits of working together.
Reverse mergers give and they take away
Investors in Conatus, and especially those in Newlink, should question how valuations of the groups' reversing acquirers have been calculated.
Morphosys gets a major tafasitamab endorsement
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
